Atrium Therapeutics Inc.
RNA | NASDAQ
$8.57
+$0.30 (+3.63%)
Nov 2, 2026, 12:04 PM ET · Market open
TTM Period Ending | TTM 2026 Jun 30, 2026 | TTM 2026 Mar 31, 2026 | TTM 2025 Dec 31, 2025 |
|---|---|---|---|
PE Ratio | -3.49 | -5.01 | -3.29 |
PEG Ratio | -0.16 | 0.12 | n/a |
PS Ratio | 9.79 | 11.16 | 13.56 |
PB Ratio | 1.07 | 0.98 | 1.22 |
P/FCF Ratio | -4.01 | -4.29 | -5.93 |
P/OCF Ratio | -4.24 | -4.54 | -6.14 |
OCF/S Ratio | -231.17 | -245.90 | -220.91 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 |
Quick Ratio | 8.73 | 13.04 | 6.53 |
Current Ratio | 8.73 | 13.04 | 6.53 |
Asset Turnover | 0.08 | 0.07 | 0.07 |
Interest Coverage | n/a | n/a | n/a |
Return on Equity | -42.90% | -33.47% | -36.99% |
Return on Assets | -33.22% | -24.97% | -27.55% |
Return on Invested Capital | -35.21% | -24.62% | -31.92% |
Dividend Yield | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a |
Gross Profit Margin | 97.90% | 99.26% | 100% |
Net Profit Margin | -396.52% | -356.15% | -411.88% |
Pretax Profit Margin | -397.13% | -356.84% | -412.64% |
Operating Profit Margin | -410.23% | -360% | -412.58% |
FCF Margin | -244% | -260.43% | -228.67% |
EBITDA Margin | -404.56% | -355.17% | -410.91% |
Add to Watchlist
Select watchlists to add or remove RNA